Page 13 - hypertension_newsletter6

REFLECTIONS
Hypertension
Hypertension Global Newsletter #6 2024

Hypertension

Presence of certain clinical red flags should prompt the clinician to consider non-adherence. The authors suggest that chemical
adherence testing using serum or urine antihypertensive levels is the best method so far and should be used if available.
Alternatively, they suggest checking for prescription refills in the electronic medical records or directly observed therapy (in which
the patient is observed swallowing the prescribed medicine under direct supervision) with subsequent ABPM measurements. Other
options to improve adherence include simplifying treatment schedules and using fixed combinations to reduce pill burden.

The author concludes that establishing a good relationship
CLINICAL PEARLS FROM THE FACULTY between the physician and patient and using a non-judgmental

approach to identify specific problems that may be causing
non-adherence in particular individuals may contribute to better
control of hypertension, lower occurrence of organ damage and
better prognosis for hypertensive patients.

CLICK HERE
WATCH FOR THE LINK TO FULL ARTICLE
DR. FIKRLE DISCUSS THE CLINICAL
IMPLICATIONS OF THESE RESULTS ON
EVERYDAY PRACTICE.

A real-world analysis of outcomes and healthcare costs of patients on perindopril/
indapamide/amlodipine single-pill vs. multiple-pill combination in Italy.
Snyman JR, et al. J Hypertens. 2024 Jan 1;42(1):136-142.

This real-world, observational, retrospective study compared the adherence, CV events, all-cause mortality incidence, and
healthcare costs among hypertensive patients who received treatment with a single-pill combination (SPC) of perindopril/
indapamide/amlodipine (PER/IND/AML) vs. a multiple-pill combination.

TABLE OF CONTENTS